Professor John Burn, from the Institute of Human Genetics at Newcastle University told the congress ECCO 15 - ESMO 34 held in Berlin on September 21 2009, that he believed that he and his colleagues may have uncovered a simple way of controlling cancer stem cells, which are essential to the formation of malignant tumours.
The clinical trial, which involved 1071 carriers of the Lynch syndrome mutation in 42 centres worldwide, randomised participants to a daily dose of 600mg aspirin and/or 30g Novelose, a resistant starch that escapes digestion in the small intestine.See also a video (00:11:18) of Prof John Burn, who "talks to ecancer editor Prof Gordon McVie about the results of his trial" (posted September 23, 2009).
And, Aspirin protects against colorectal cancer, says international clinical trial, News Release, ECCO 15 – ESMO 34, September 21, 2009. Excerpt:
The mechanism by which aspirin protects against cancer has yet to be elucidated, but the scientists believe that cancer stem cells are involved.Also, Aspirin taking on colon cancer, Mark Gertskis, Pharmacy News, September 28, 2009.
Comment: A heads-up: Daily dose of aspirin not safe for everyone, Jodi Mailander Farrell, MiamiHerald.com, September 29, 2009.